Trials / Completed
CompletedNCT03170180
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study. 2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib). 3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs. 4. Patients will be evaluated every 6 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib | sunitinib 37.5mg daily |
| DRUG | Gefitinib | Gefitinib 250mg daily |
| DRUG | Imatinib | Imatinib 400mg daily |
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2021-10-31
- Completion
- 2021-12-28
- First posted
- 2017-05-30
- Last updated
- 2022-06-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03170180. Inclusion in this directory is not an endorsement.